Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 2Suspended 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 5Gastrointestinal 4Genitourinary 3Thoracic 2Sarcoma 1Head & Neck 1Gynecologic 1

Conditions

Pancreatic Neoplasms 1Locally Advanced Rectal Adenocarcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 328Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 257lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
sotigalimab × Gastrointestinal × Clear all
NCT05419479 2026-06-04

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended
46 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04130854 2026-05-06

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

University of Texas Southwestern Medical Center

Phase 2 Completed
58 enrolled
Gastrointestinal

Locally Advanced Rectal Adenocarcinoma

NCT02600949 2026-04-24

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
300 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03165994 2024-05-02

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

Apexigen America, Inc.

Phase 2 Completed
34 enrolled 18 charts
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡